Rhythm Pharmaceuticals Inc [RYTM] stock prices are up 2.97% to $59.55 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RYTM shares have gain 26.84% over the last week, with a monthly amount glided 18.53%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] stock has seen the most recent analyst activity on April 07, 2025, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $63 for it. On January 02, 2025, Jefferies initiated with a Buy rating and assigned a price target of $80 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $76 on December 20, 2024. Guggenheim initiated its recommendation with a Buy and recommended $70 as its price target on October 21, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on September 18, 2024, and assigned it a price target of $64. In a note dated September 17, 2024, JMP Securities initiated an Mkt Outperform rating and provided a target price of $64 on this stock.
The stock price of Rhythm Pharmaceuticals Inc [RYTM] has been fluctuating between $35.17 and $68.58 over the past year. Currently, Wall Street analysts expect the stock to reach $71.6 within the next 12 months. Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] shares were valued at $59.55 at the most recent close of the market. An investor can expect a potential return of 20.24% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
The Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] reported sales of 130.13M for trailing twelve months, representing a surge of 72.61%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -2.04%, Pretax Profit Margin comes in at -2.0%, and Net Profit Margin reading is -2.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.67, Equity is -3.79 and Total Capital is -0.96. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 57.07 points at the first support level, and at 54.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 61.07, and for the 2nd resistance point, it is at 62.60.
Ratios To Look Out For
It’s worth pointing out that Rhythm Pharmaceuticals Inc [NASDAQ:RYTM]’s Current Ratio is 3.24. Further, the Quick Ratio stands at 3.08, while the Cash Ratio is 0.77. Considering the valuation of this stock, the price to sales ratio is 28.93, the price to book ratio is 170.99.
Transactions by insiders
Recent insider trading involved Cramer Pamela J., Chief Human Resources Officer, that happened on Apr 08 ’25 when 20760.0 shares were sold. EVP, Head of International, Mazabraud Yann completed a deal on Apr 08 ’25 to sell 17750.0 shares. Meanwhile, Officer PAMELA CRAMER bought 20760.0 shares on Apr 08 ’25.
